Radiopharm Theranostics has increased its ownership stake in Radiopharm Ventures, a joint venture created with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%. Radiopharm's decision to increase the ownership percentage comes as the joint venture continues to show promising progress in its cancer therapeutic pipeline, including the advancement of its leading B7H3 candidate and other preclinical assets. B7H3 is an immune checkpoint protein that is very infrequently seen in healthy cells but is consistently overexpressed in the majority of cancer tissues. High expression of B7H3 in cancer is associated with greater tumor size and lymphatic invasion. The lead candidate monoclonal antibody radiolabelled with 177Lu, Betabart, targets B7H3 and successfully received Investigational New Drug clearance in July 2025 by the U.S. Food and Drug Administration. The first patient in this Phase 1 therapeutic trial is expected to be dosed in Q1 2026, with a number of centers already activated. Additionally, two other preclinical candidates have demonstrated early positive results and have progressed towards final candidate selection, with potential applications across multiple solid tumor types.
Wall Street analysts forecast RADX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RADX is 20.33 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast RADX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RADX is 20.33 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.050
Low
15.00
Averages
20.33
High
30.00
Current: 5.050
Low
15.00
Averages
20.33
High
30.00
Maxim
Michael Okunewitch
NULL -> Buy
upgrade
$12 -> $15
2025-12-17
Reason
Maxim
Michael Okunewitch
Price Target
$12 -> $15
AI Analysis
2025-12-17
upgrade
NULL -> Buy
Reason
Maxim analyst Michael Okunewitch raised the firm's price target on Radiopharm to $15 from $12 and keeps a Buy rating on the shares. The firm cites the company having announced positive results on its primary endpoint in an interim analysis of the first 12 patients in the Phase 2b study of RAD 101, as the study demonstrated concordance with MRI in 92% of patients treated with RAD 101 as a PET imaging agent for brain metastases, the analyst tells investors in a research note. The initial data emerging from the Phase 2b study of RAD 101 in brain metastasis imaging is highly encouraging and de-risks Radopharm's potential to address the $500M market opportunity in brain mets diagnostics and monitoring, the firm added.
B. Riley
B. Riley
Buy
maintain
$13 -> $16
2025-12-16
Reason
B. Riley
B. Riley
Price Target
$13 -> $16
2025-12-16
maintain
Buy
Reason
B. Riley raised the firm's price target on Radiopharm to $16 from $13 and keeps a Buy rating on the shares. Radiopharm reported positive interim Phase 2b imaging data for RAD101 in brain metastases, with 92% MRI concordance and clear, selective tumor uptake consistent with prior Phase 2a results, the analyst tells investors in a research note. Enrollment is over 50% in the 30-patient study, with final data expected in the first half of 2026 to inform Phase 3 design ahead of a planned FDA meeting in mid-2026, B. Riley adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RADX
Unlock Now
B. Riley
Buy
downgrade
$15 -> $13
2025-11-26
Reason
B. Riley
Price Target
$15 -> $13
2025-11-26
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Radiopharm to $13 from $15 and keeps a Buy rating on the shares. Radiopharm, which recently reported clinical progress across four lead programs, has an attractive risk/reward profile with key catalysts expected over the next 6-12 months, the analyst tells investors in a research note. With two additional assets entering clinics, some of Radiopharm's clinical-stage assets may be pursued by pharma when the market's interest in RLT returns, the firm says.
Brookline
Kemp Dolliver
Buy
initiated
$18
2025-07-21
Reason
Brookline
Kemp Dolliver
Price Target
$18
2025-07-21
initiated
Buy
Reason
Brookline analyst Kemp Dolliver initiated coverage of Radiopharm with a Buy rating and $18 price target. The clinical stage company's pipeline of radiopharmaceutical candidates features novel combinations of targeting moieties, isotopes, and tumor types and is early stage with six of seven programs at either the preclinical stage or in Phase 1, notes the analyst. The company's most advanced candidate, RAD101, is an imaging candidate for brain metastases that is in a Phase 2b study with data from the first two cohorts expected in Q3, the analyst points out.
About RADX
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
